During the H1N1 swine flu pandemic, much criticism was leveled at World Health Organization officials, accusing their response of being too heavily influenced by the pharmaceutical industry. But according to a panel of independent experts, that wasn't the case.
The company has landed a lucrative flu-vaccine contract with the U.S. government. It's worth $97 million over the first three years, and it can be extended for an additional two years, for a total contract value of $179.1 million. The technology could prove to be a lifesaver.
Though the threat of H1N1 infection remains, the World Health Organization has declared an end to the Swine Flu pandemic, citing "pure good luck" to explain why the disease wasn't as lethal as feared.
A biotech with a novel method of making vaccines, has a promising swine flu drug. So far, so good, but it's hardly a lock
